Bristol Myers Squibb Company may have entered a new era under new CEO Christopher Boerner, who took the helm from retiring CEO Giovanni Caforio in November – an era in which the company more aggressively looks to fill gaps in its portfolio through mergers and acquisitions. Bristol announced on 26 December that it would pay $4.1bn for RayzeBio, Inc., just four days after BMS said it would buy Karuna Therapeutics, Inc. for $14bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?